Cover Image
市場調查報告書

CytImmune Sciences, Inc. - 產品平台檢討

CytImmune Sciences, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 277763
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
CytImmune Sciences, Inc. - 產品平台檢討 CytImmune Sciences, Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 24 Pages
簡介

CytImmune Sciences, Inc.是總公司設置於美國,正在進行基於奈米醫藥,以腫瘤為標的之治療藥的藥物研發·開發·商品化的企業。產品用於前列腺癌、黑色素瘤、軟組織肉瘤、卵巢癌、乳癌等治療。該公司也利用健康捐贈者的淋巴球來開發人體單株抗體治療藥。

本報告提供CytImmune Sciences, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

CytImmune Sciences, Inc.的基本資料

  • CytImmune Sciences, Inc.概要
  • 主要資訊
  • 企業資料

CytImmune Sciences, Inc.:R&D概要

  • 主要的治療範圍

CytImmune Sciences, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

CytImmune Sciences, Inc.:開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

CytImmune Sciences, Inc.:藥物簡介

  • CYT-6091
  • CYT-21000
  • CYT-61000
  • CYT-71000

CytImmune Sciences, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

CytImmune Sciences, Inc.:最新的開發平台資訊

CytImmune Sciences, Inc.:開發暫停中的計劃

CytImmune Sciences, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07026CDB

Summary

Global Markets Direct's, 'CytImmune Sciences, Inc. - Product Pipeline Review - 2015', provides an overview of the CytImmune Sciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CytImmune Sciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CytImmune Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CytImmune Sciences, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CytImmune Sciences, Inc.'s pipeline products

Reasons to buy

  • Evaluate CytImmune Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CytImmune Sciences, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CytImmune Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CytImmune Sciences, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytImmune Sciences, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CytImmune Sciences, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CytImmune Sciences, Inc. Snapshot
    • CytImmune Sciences, Inc. Overview
    • Key Information
    • Key Facts
  • CytImmune Sciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • CytImmune Sciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CytImmune Sciences, Inc. - Pipeline Products Glance
    • CytImmune Sciences, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • CytImmune Sciences, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • CytImmune Sciences, Inc. - Drug Profiles
    • CYT-6091
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CYT-21000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CYT-61000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CYT-71000
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CytImmune Sciences, Inc. - Pipeline Analysis
    • CytImmune Sciences, Inc. - Pipeline Products by Target
    • CytImmune Sciences, Inc. - Pipeline Products by Route of Administration
    • CytImmune Sciences, Inc. - Pipeline Products by Molecule Type
    • CytImmune Sciences, Inc. - Pipeline Products by Mechanism of Action
  • CytImmune Sciences, Inc. - Recent Pipeline Updates
  • CytImmune Sciences, Inc. - Dormant Projects
  • CytImmune Sciences, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CytImmune Sciences, Inc., Key Information
  • CytImmune Sciences, Inc., Key Facts
  • CytImmune Sciences, Inc. - Pipeline by Indication, 2015
  • CytImmune Sciences, Inc. - Pipeline by Stage of Development, 2015
  • CytImmune Sciences, Inc. - Monotherapy Products in Pipeline, 2015
  • CytImmune Sciences, Inc. - Phase I, 2015
  • CytImmune Sciences, Inc. - Preclinical, 2015
  • CytImmune Sciences, Inc. - Discovery, 2015
  • CytImmune Sciences, Inc. - Pipeline by Target, 2015
  • CytImmune Sciences, Inc. - Pipeline by Route of Administration, 2015
  • CytImmune Sciences, Inc. - Pipeline by Molecule Type, 2015
  • CytImmune Sciences, Inc. - Pipeline Products by Mechanism of Action, 2015
  • CytImmune Sciences, Inc. - Recent Pipeline Updates, 2015
  • CytImmune Sciences, Inc. - Dormant Developmental Projects,2015

List of Figures

  • CytImmune Sciences, Inc. - Pipeline by Stage of Development, 2015
  • CytImmune Sciences, Inc. - Monotherapy Products in Pipeline, 2015
  • CytImmune Sciences, Inc. - Pipeline by Top 10 Target, 2015
  • CytImmune Sciences, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • CytImmune Sciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top